<div id="readability-page-1"><h3>Memorial Day Sale – Claim 70% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul>An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available. CSPC Pharmaceutical Group reported first-quarter 2026 revenue of RMB6.47 billion, down 7.8% year on year, with profit attributable to shareholders falling 41.8% to RMB860 million. The sharp profit decline was mainly driven by a steep drop in licence fee income compared with the prior-year period, when the group booked a large upfront payment under exclusive licensing deals. Excluding licence fees, profit attributable to shareholders decreased a milder 7.3% to RMB736 million, while underlying profit fell 40.3% as investment-related fair value changes and share-based expenses weighed on earnings. Finished drug sales of goods grew 6.2%, supported by strong nervous system and cardiovascular products, but overall finished drug revenue slipped 5% as licence fee income plunged nearly 80%, underscoring the group’s increased earnings sensitivity to one-off licensing revenue. The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page. More about CSPC Pharmaceutical Group CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on finished drugs, bulk products, and functional foods. Its core portfolio spans therapeutic areas including nervous system, oncology, anti-infectives, cardiovascular, respiratory, and digestive and metabolic diseases, with a growing emphasis on innovative finished drug sales and licensing partnerships. Average Trading Volume: 86,347,378 Technical Sentiment Signal: Hold Current Market Cap: HK$88.46B For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.</div>

01093

159570

159506

510660

562050

512010

CSPC Pharmaceutical Group reported a 7.8% decline in Q1 2026 revenue to RMB6.47 billion, with profit attributable to shareholders dropping 41.8% to RMB860 million, primarily due to a significant decrease in licence fee income. Finished drug sales grew 6.2%, but overall revenue fell 5%. Analysts maintain a Buy rating on the stock with a price target of HK$13.05.

CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income